MedPath

PF-03654746

Generic Name
PF-03654746
Drug Type
Small Molecule
Chemical Formula
C18H24F2N2O
CAS Number
935840-31-6
Unique Ingredient Identifier
G3QE979K1X
Background

PF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome, and Excessive Daytime Sleepiness.

Clinical Trials
Related News

Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome

Phase 2
Withdrawn
Conditions
Tourette's Syndrome
Interventions
Drug: Placebo
First Posted Date
2011-11-21
Last Posted Date
2019-04-01
Lead Sponsor
Pfizer
Registration Number
NCT01475383
Locations
🇺🇸

Pfizer Investigational Site, Manhasset, New York, United States

Add On Treatment for Cognitive Deficits in Schizophrenia

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Other: Placebo
First Posted Date
2011-05-02
Last Posted Date
2011-05-02
Lead Sponsor
University of Pennsylvania
Target Recruit Count
16
Registration Number
NCT01346163
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

Phase 1
Terminated
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
First Posted Date
2009-12-09
Last Posted Date
2014-06-04
Lead Sponsor
Pfizer
Target Recruit Count
9
Registration Number
NCT01028911
Locations
🇺🇸

Pfizer Investigational Site, Wichita, Kansas, United States

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

Phase 2
Completed
Conditions
Excessive Daytime Sleepiness
Narcolepsy
Interventions
Drug: Placebo
First Posted Date
2009-11-01
Last Posted Date
2014-05-09
Lead Sponsor
Pfizer
Target Recruit Count
95
Registration Number
NCT01006122
Locations
🇺🇸

Pfizer Investigational Site, Houston, Texas, United States

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

Phase 2
Completed
Conditions
Allergic Rhinitis
Interventions
Drug: Placebo
First Posted Date
2007-11-21
Last Posted Date
2014-04-16
Lead Sponsor
Pfizer
Target Recruit Count
21
Registration Number
NCT00562120
Locations
🇺🇸

Pfizer Investigational Site, Omaha, Nebraska, United States

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Phase 2
Completed
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Drug: Placebo capsules
First Posted Date
2007-09-19
Last Posted Date
2016-02-19
Lead Sponsor
Pfizer
Target Recruit Count
66
Registration Number
NCT00531752
Locations
🇺🇸

Bay Area Research Institute, Lafayette, California, United States

🇺🇸

Pharmacology Research Institute, Newport Beach, California, United States

🇺🇸

New York University School of Medicine, New York, New York, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy